Science Corporation's $400 Million Series D Prices It at $3.5 Billion, 2.3 Times March
Startups / news
Science Corporation's $400 Million Series D Prices It at $3.5 Billion, 2.3 Times March
The company's own post names no valuation or lead, and its total-raised figure does not match the arithmetic.

Science Corporation announced a $400 million Series D on November 17, and TechCrunch reported that investors valued the brain-interface company at $3.5 billion. The company's own post names no valuation and no lead investor.
The valuation is the number to watch. Crunchbase reported that Science's $230 million Series C, announced March 5, put the company at a reported $1.5 billion. The new figure is 2.3 times that, reached in 257 days.
The round: $400 million, valuation unconfirmed
Science's Series D post lists Khosla Ventures, Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech as participants, "among others." It does not say who led. TechCrunch attributes the $3.5 billion figure to a person familiar with the deal, not to Science.
If $3.5 billion is post-money, the round sold 11.4% of the company. The Terminal cannot confirm which basis applies.

Max Hodak, the company's co-founder and chief executive and a former president of Neuralink, founded Science in 2021.
The totals do not quite add up
Science's post says it has raised "more than $900 million" since 2021. Crunchbase put total funding at $489 million after the Series C. Adding $400 million gives $889 million, which is below $900 million. Either earlier capital was counted differently or the company is rounding up. Neither source resolves it.
| Round | Date | Amount | Reported valuation |
|---|---|---|---|
| Series C | Mar. 5, 2026 | $230 million | $1.5 billion (reported, not disclosed) |
| Series D | Nov. 17, 2026 | $400 million | $3.5 billion (TechCrunch) |
What the money is for: PRIMA
The product is PRIMA, a retinal implant. Science calls it the first brain-computer interface to be CE marked to restore form vision, meaning the ability to read letters, numbers and words. It is indicated for patients blinded by certain late-stage macular degeneration. The post says the European commercial launch happened a few months before the round, and TechCrunch says it is available in Germany.
The Series D funds three things per the company: faster availability across Europe, a U.S. launch through the FDA's Humanitarian Device Exemption, and manufacturing and research capacity. TechCrunch says Science has argued to the FDA that advanced macular degeneration in both eyes is rare enough to qualify. An exemption is not approval, and the post says U.S. approval is still being pursued.
Two dated milestones sit in the company's news feed. On October 5 it published 36-month PRIMA trial results in patients with geographic atrophy. On October 13 it posted video of the first patient with Stargardt disease treated with PRIMA. The post gives no patient count or price.
The longer bet
The valuation jump echoes other physical-tech rounds, such as Genesis AI's $500 million at $3.5 billion, which landed at the same headline valuation. Software rounds such as LangChain's Series C priced at 2.4 times the prior mark; Science's step-up is similar in size with no revenue disclosed. A fund evaluating either company is weighing a product that has to clear regulators or factories before revenue.
The company also wants a "bio-hybrid sensor built from a combination of cultured neurons and silicon," per TechCrunch. It is designing first human trials with Murat Günel, a Yale neurosurgery professor, who said the technology could help treat Parkinson's disease and other brain injuries. No trial date is given.
Science named Darius Shahida its president on September 17.
The next checkpoint is an FDA response on the exemption. The company has not given a date.
Sources
More in Startups
- 01Rediff Files Updated IPO Papers: ₹600 Crore Fresh Issue on ₹133.6 Crore of RevenueThe AvenuesAI subsidiary reports FY26 revenue up 258.7% and net profit of ₹55.9 crore, while net debt rose ₹93.47 crore in one quarter.
- 02Plural Closes €1 Billion, and Two Reports Split It DifferentlyTechCrunch says two-thirds goes to Fund III and one-third to an opportunities fund; Crunchbase News calls the whole sum the third fund.
- 03Bharat Semi Raises $24 Million Seed for Image Sensors It Has Not Yet SoldThe pre-revenue New Delhi startup has two design wins, a 70% system-cost claim nobody has independently tested, and customer delivery targeted for the end of 2027.
- 04Shree Anandhaas Raises ₹110 Crore at About ₹1,908 Crore, 3.3 Times Its Last RoundEntrackr's valuation implies roughly 250 times FY25 profit for the Coimbatore sweets chain, and the earlier round was part secondary.